Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple combination therapy with lopinavir, ritonavir and hydroxychloroquine for COVID-19
jRCTs031190227Completed
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lopinavir, ritonavir, hydroxychloroquine and oseltamivir in coronavirus disease 2019 (COVID-19). Primary endpoint: C-reactive protein ratio before versus after treatment. Started Apr 2020; status: completed.
02
Drugs
lopinavirritonavirhydroxychloroquineoseltamivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031190227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190227.